We anticipate continued follow-up from this study to aid the encouraging findings so far. We also anticipate initiating a large, randomized and controlled scientific study for AGS-003 in combination with sunitinib in 2011. The study’s primary endpoint is to evaluate medical activity as measured by objective tumor response. Secondary endpoints included basic safety, clinical advantage , immunologic response, and assessment of both progression-free of charge and overall survival.. Argos’ AGS-003 in conjunction with sunitinib demonstrates favorable PFS for renal cell carcinoma Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma , AGS-003, demonstrated favorable progression-free survival and safety in conjunction with sunitinib, based on updated results from an ongoing Stage 2 trial.Home Panel Backs Medicaid Legislation A Republican-led Home committee approved a plan to expand and remake Missouri's Medicaid program Wednesday, but it may never take effect since it falls short of the needs of President Barack Obama's health care legislation. The legislation would authorize a fivefold upsurge in Missouri's income eligibility thresholds for adults to qualify for Medicaid. Yet it could not go as far as Obama's administration has said is essential for states to receive full federal financing for the Medicaid growth .